Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Finance

26 Aug 2023

GH Research Reports Q2 2023 Financial Results and Business Update

GH Research has reported its second quarter 2023 financial results, with updates on trials and cash on hand....

By Microdose NewsDesk
psychedelic news

Don’t Miss

21 Aug 2023

News You Might Have Missed: Aug 21st, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk
mushrooms

Breaking News

16 Aug 2023

COMPASS Pathways Announces Capital Raise of Up to $285 Million

COMPASS Pathways has announced a capital raise of up to $285 million, the largest cash injection the industry has seen in quite some time....

By Microdose NewsDesk
mushrooms

Finance

15 Aug 2023

MindMed Secures $50 Million Loan From K2 HealthVentures

MindMed secures $50 Million credit facility with K2 HealthVentures, giving company access to additional capital...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

psychedelic news

Don’t Miss

14 Aug 2023

News You Might Have Missed: Aug 14th, 2023

A weekly roundup of psychedelic medicine news to help you catch up and stay informed. Highlights include news from atai Life Sciences and new psychedelic research....

By Microdose NewsDesk

Industry

10 Aug 2023

First Professional Practice Guidelines Published for Psychedelic-Assisted Therapy

The American Psychedelic Practitioners Association (APPA) has released the first-ever set of professional practice guidelines for psychedelic-assisted therapy....

By Microdose NewsDesk

Breaking News, Industry

9 Aug 2023

atai Life Sciences Announces Results of New Phase 1 Study of PCN-101 (R-Ketamine)

Atai announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine)....

By Microdose NewsDesk

Industry

8 Aug 2023

Filament Health Announces FDA Approval of Two Clinical Trials

FDA has approved two clinical trials studying the effects of PEX010, Filament's botanical psilocybin drug candidate....

By Microdose NewsDesk

Industry

8 Aug 2023

Algernon NeuroScience Announces Phase 2 DMT Stroke Study

Algernon NeuroScience has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study....

By Microdose NewsDesk

Follow us on social

Latest News

Medical Psilocybin Act

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

You Might Also Like

9 Feb 2026

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin...

By Madison Roberts

19 Jan 2026

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics....

By Madison Roberts

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.